Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 500 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.
Follow-Up Questions
PHMMF 주식의 가격 성능은 어떻습니까?
PHMMF의 현재 가격은 $93이며, 전 거래일에 decreased 0% 하였습니다.
Pharma Mar SA의 주요 사업 주제나 업종은 무엇입니까?
Pharma Mar SA은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Pharma Mar SA의 시가총액은 얼마입니까?
Pharma Mar SA의 현재 시가총액은 $1.5B입니다
Pharma Mar SA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 10명의 분석가가 Pharma Mar SA에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 6명의 매수, 3명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다
